Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | EEF2K | O00418 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | PRKX | P51817 | 1/20 | 0.40 |
| ▸ | NEK4 | P51957 | 1/20 | 0.40 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.40 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.40 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.40 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20348862 | 0.85 | EGFR (0.43) | EGFRITKTAOK1CLK4ROCK2 | |
| SCHEMBL18345074 | 0.85 | EGFR (0.43) | EGFRITKTAOK1CLK4ROCK2 | |
| SCHEMBL16834691 | 0.84 | ROCK2 (0.45) | EGFRITKTAOK1CLK4ROCK2 | |
| SCHEMBL26204290 | 0.84 | EGFR (0.43) | EGFRITKTAOK1CLK4ROCK2 | |
| SCHEMBL30237888 | 0.84 | ROCK2 (0.45) | EGFRITKTAOK1CLK4ROCK2 | |
| SCHEMBL12058336 | 0.84 | EGFR (0.41) | EGFRITKTAOK1CLK4ROCK2 | |
| SCHEMBL28936153 | 0.83 | HSP90AB1 (0.43) | EGFRITKTAOK1CLK4ROCK2 | |
| SCHEMBL389988 | 0.82 | EGFR (0.44) | EGFRITKTAOK1CLK4ROCK2 | |
| SCHEMBL387774 | 0.82 | EGFR (0.44) | EGFRITKTAOK1CLK4ROCK2 | |
| SCHEMBL829659 | 0.81 | ROCK2 (0.43) | EGFRITKTAOK1CLK4ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | WEE1, PRMT1, ABL1 | EGFR 724/4885ITK 341/4885TAOK1 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.